Epithelial Ovarian CancerPractice Guidelines in Oncology

[1]  Jeffrey J H Low,et al.  Epithelial ovarian cancer , 2018, An Atlas of Gynecologic Oncology.

[2]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[3]  G. Rustin,et al.  How to follow-up patients with epithelial ovarian cancer , 2010, Current opinion in oncology.

[4]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[5]  V. Gebski,et al.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Monk,et al.  Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Bast.  CA 125 and the detection of recurrent ovarian cancer , 2010, Cancer.

[8]  Thomas Lindblad,et al.  Different volatile signals emitted by human ovarian carcinoma and healthy tissue. , 2010, Future oncology.

[9]  N. Weiss,et al.  Predictive value of symptoms for early detection of ovarian cancer. , 2010, Journal of the National Cancer Institute.

[10]  R. Bast,et al.  Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. , 2010, Gynecologic oncology.

[11]  B. Karlan,et al.  Ovarian cancer: the duplicity of CA125 measurement , 2010, Nature Reviews Clinical Oncology.

[12]  Richard G. Moore,et al.  A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). , 2010 .

[13]  A. Oza,et al.  Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. , 2010 .

[14]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Reuss,et al.  Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Hatae,et al.  Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Markman,et al.  CA-125 Monitoring in Ovarian Cancer: Patient Survey Responses to the Results of the MRC/EORTC CA-125 Surveillance Trial , 2010, Oncology.

[18]  Susanna I. Lee,et al.  MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. , 2010, AJR. American journal of roentgenology.

[19]  Gary Goodman,et al.  Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study , 2010, Journal of the National Cancer Institute.

[20]  P. Hartge.  Designing early detection programs for ovarian cancer. , 2010, Journal of the National Cancer Institute.

[21]  D. Clarke‐Pearson,et al.  Screening for Ovarian Cancer , 2009 .

[22]  M. Bookman.  Dose-dense chemotherapy in advanced ovarian cancer , 2009, The Lancet.

[23]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[24]  P. Schiff,et al.  Fertility preservation in young women with epithelial ovarian cancer , 2009, Cancer.

[25]  S. Huffel,et al.  Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses , 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[26]  M. Nucci,et al.  Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria , 2009, Modern Pathology.

[27]  B. Karlan,et al.  Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. , 2009, Gynecologic oncology.

[28]  E. Løkkegaard,et al.  Hormone therapy and ovarian cancer. , 2009, JAMA.

[29]  S. Braun,et al.  Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. , 2009, Anticancer research.

[30]  W. Cliby,et al.  Pattern of retroperitoneal dissemination of primary peritoneum cancer: basis for rational use of lymphadenectomy. , 2009, Gynecologic oncology.

[31]  B. van Calster,et al.  Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? , 2009, British Journal of Cancer.

[32]  G. Rustin,et al.  A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Robert S Mannel,et al.  Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Timothy R Church,et al.  Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial , 2009, Obstetrics and gynecology.

[35]  A. Loft,et al.  Influence of 2-(18F) Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography on Recurrent Ovarian Cancer Diagnosis and on Selection of Patients for Secondary Cytoreductive Surgery , 2009, International Journal of Gynecologic Cancer.

[36]  L. Asmar,et al.  Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Alberts,et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Jacobus Pfisterer,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[39]  M. Markman.  An Update on the Use of Intraperitoneal Chemotherapy in the Management of Ovarian Cancer , 2009, Cancer journal.

[40]  D. Alberts,et al.  Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009. , 2009, Gynecologic oncology.

[41]  C. Crum,et al.  Serous Tubal Intraepithelial Carcinoma and the Dominant Ovarian Mass: Clues to Serous Tumor Origin? , 2009, The American journal of surgical pathology.

[42]  M. Fulham,et al.  The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. , 2009, Gynecologic oncology.

[43]  L. Stead,et al.  Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis , 2009, International journal of emergency medicine.

[44]  P. Colombo,et al.  Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[45]  Susan M. Domchek,et al.  Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers , 2009, Journal of the National Cancer Institute.

[46]  U. Matulonis,et al.  Food , drug , insect sting allergy , and anaphylaxis Hypersensitivity reactions to chemotherapy : Outcomes and safety of rapid desensitization in 413 cases , 2022 .

[47]  M. Muto,et al.  Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  N. Urban,et al.  Combining a symptoms index with CA 125 to improve detection of ovarian cancer , 2008, Cancer.

[49]  M. Deavers,et al.  Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. , 2008, Gynecologic oncology.

[50]  D. Jurkovic,et al.  Simple ultrasound‐based rules for the diagnosis of ovarian cancer , 2008, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[51]  György Horvath,et al.  Human Ovarian Carcinomas Detected by Specific Odor , 2008, Integrative cancer therapies.

[52]  Richard G. Moore,et al.  Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer , 2008 .

[53]  U. Dafni,et al.  High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial , 2008, Bone Marrow Transplantation.

[54]  D. Katsaros,et al.  Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[56]  R. Barakat,et al.  The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. , 2008, Gynecologic oncology.

[57]  Michael W Sill,et al.  Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  Howard Mackey,et al.  Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  P. Rose,et al.  Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. , 2007, Gynecologic oncology.

[60]  A. Oza,et al.  Optimal chemotherapy treatment for women with recurrent ovarian cancer , 2007, Current oncology.

[61]  A. Weaver,et al.  How Relevant Are ACOG and SGO Guidelines for Referral of Adnexal Mass? , 2007, Obstetrics and gynecology.

[62]  J. Ledermann,et al.  Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  M. Valerio,et al.  Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  A. Fader,et al.  Role of surgery in ovarian carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  P. Neven,et al.  Management of borderline ovarian neoplasms. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  D. Mutch,et al.  Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  R. Kimmig,et al.  Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). , 2007, Gynecologic oncology.

[68]  J. Fine,et al.  Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial. , 2007, Gynecologic oncology.

[69]  H. Lenz.  Management and preparedness for infusion and hypersensitivity reactions. , 2007, The oncologist.

[70]  C. Thomssen,et al.  Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. , 2007, Gynecologic oncology.

[71]  R. Barakat,et al.  Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer , 2007, Cancer.

[72]  R. Berkowitz,et al.  Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.

[73]  D. Cella,et al.  Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  N. Urban,et al.  Development of an ovarian cancer symptom index , 2007 .

[75]  D. Levine,et al.  The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. , 2006, Gynecologic oncology.

[76]  E. Eisenhauer,et al.  Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  A. Reuss,et al.  Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. , 2006, Gynecologic oncology.

[78]  M. Gore,et al.  Intraperitoneal chemotherapy in ovarian cancer remains experimental. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  M. Brady,et al.  Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  A. Whittemore,et al.  Patterns and Progress in Ovarian Cancer Over 14 Years , 2006, Obstetrics and gynecology.

[81]  Jeffrey Bell,et al.  Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.

[82]  D. Bodurka,et al.  A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. , 2006, Gynecologic oncology.

[83]  F. Couch,et al.  Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. , 2006, JAMA.

[84]  J. Seidman,et al.  Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. , 2006, Gynecologic Oncology.

[85]  D. Mutch,et al.  Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma , 2006, Cancer.

[86]  S. Waggoner,et al.  Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.

[87]  M. Markman.  Management of ovarian cancer. An impressive history of improvement in survival and quality of life. , 2006, Oncology.

[88]  D. Hepner,et al.  Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. , 2006, Annals of emergency medicine.

[89]  Joan L. Walker,et al.  Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Christopher P Crum,et al.  The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.

[91]  A. Oza,et al.  A retrospective analysis of neoadjuvant platinum‐based chemotherapy versus up‐front surgery in advanced ovarian cancer , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[92]  Deborah Schrag,et al.  Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. , 2006, Journal of the National Cancer Institute.

[93]  R. Burger,et al.  Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.

[94]  W. Cliby,et al.  Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer , 2006, Obstetrics and gynecology.

[95]  Gautam G. Rao,et al.  Hormonal therapy in epithelial ovarian cancer , 2006, Expert review of anticancer therapy.

[96]  N. Hacker,et al.  Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. , 2005, Journal of the National Cancer Institute.

[97]  B. Rosen,et al.  Who should operate on patients with ovarian cancer? An evidence-based review. , 2005, Gynecologic oncology.

[98]  U. Matulonis,et al.  Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. , 2005, Gynecologic oncology.

[99]  E. Trimble,et al.  2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  P. Rose.  Gemcitabine reverses platinum resistance in platinum‐resistant ovarian and peritoneal carcinoma , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[101]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[102]  K. Hatch,et al.  Validation of Referral Guidelines for Women With Pelvic Masses , 2005, Obstetrics and gynecology.

[103]  S. Rubin,et al.  Secondary surgical cytoreduction for advanced ovarian carcinoma. , 2004, The New England journal of medicine.

[104]  D. Alberts,et al.  Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. , 2004, Gynecologic oncology.

[105]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[106]  U. Matulonis,et al.  Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. , 2004, Gynecologic oncology.

[107]  Steven Sun,et al.  Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. , 2004, Gynecologic oncology.

[108]  M. Dimopoulos,et al.  Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian Cancer , 2004, Oncology.

[109]  D. Alberts,et al.  Long‐term follow‐up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[110]  M. Markman,et al.  Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  U. Matulonis,et al.  Phase II trial of anastrozole in women with asymptomatic müllerian cancer. , 2003, Gynecologic oncology.

[112]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  B. Monk,et al.  Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.

[115]  P. Rose,et al.  A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.

[116]  R. Kryscio,et al.  Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. , 2002, Gynecologic oncology.

[117]  H. Gabra,et al.  CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[118]  P. Sabbatini,et al.  Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. , 2002, Gynecologic oncology.

[119]  Joos Vandewalle,et al.  Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma , 2001, The Lancet.

[120]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[121]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[122]  J A Blessing,et al.  Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  L. Mariani,et al.  Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  W. R. Hart,et al.  Ovarian papillary serous tumors of low malignant potential (Serous borderline tumors): A long term follow‐up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma , 1996, Cancer.

[125]  R. Barakat,et al.  Laparotomy to Complete Staging of Presumed Early Ovarian Cancer , 1996, Obstetrics and gynecology.

[126]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, The New England journal of medicine.

[127]  R. Barakat,et al.  Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. , 1995, Gynecologic oncology.

[128]  E. Yordan,et al.  Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  M. Buyse,et al.  The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, The New England journal of medicine.

[130]  R. Ozols,et al.  Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure , 1994, Cancer.

[131]  N. Hacker,et al.  Tamoxifen in patients with advanced epithelial ovarian cancer , 1994, International Journal of Gynecologic Cancer.

[132]  J. Woodruff,et al.  Long-term follow-up of serous ovarian tumors of low malignant potential. , 1992, Gynecologic oncology.

[133]  S. Rubin,et al.  Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  K. Hatch,et al.  Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A gynecologic oncology group study of second‐line therapy in 105 patients , 1991, Cancer.

[135]  E. Yordan,et al.  Stage III ovarian tumors of low malignant potential treated with cisplatin combination therapy (a Gynecologic Oncology Group study). , 1991, Gynecologic oncology.

[136]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[137]  S. Ellenberg,et al.  Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials , 1990, The New England journal of medicine.

[138]  D. Gershenson,et al.  Serous ovarian tumors of low malignant potential with peritoneal implants , 1990, Cancer.

[139]  A. Sood,et al.  Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. , 2010, Gynecologic oncology.

[140]  D. Chi,et al.  Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. , 2009, Gynecologic oncology.

[141]  R. Burger,et al.  Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2006, Gynecologic oncology.

[142]  M. Markman,et al.  Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions , 2003, Journal of Cancer Research and Clinical Oncology.

[143]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[144]  T. Waldron,et al.  Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. , 2001, International Journal of Radiation Oncology, Biology, Physics.

[145]  N. Spirtos,et al.  The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma , 2000, Cancer.